1. Phylogeny  
   Protein kinase C epsilon (PKCε), encoded by the PRKCE gene and identified by Uniprot Q02156, belongs to the protein kinase C (PKC) family, which is itself part of the broader AGC kinase superfamily that includes protein kinase A (PKA) and protein kinase G (PKG). PKCε is classified within the novel PKC (nPKC) subfamily, a group defined by their activation solely through lipid second messengers rather than a requirement for calcium. This subtype distinction sets novel PKCs apart from conventional PKCs, which require both calcium and diacylglycerol (DAG) along with phosphatidylserine for activation. The evolution and conservation of PKCε across eukaryotic species are reflected in its preservation of a common core set of catalytic and regulatory motifs inherited from early ancestors; these include the glycine‐rich loop and an invariant lysine critical for ATP binding. Orthologs of PKCε can be observed in all mammalian species, and phylogenetic reconstructions based on the human kinome indicate that the novel PKC isoforms share a common evolutionary origin apart from other PKC subclasses. This organization is consistent with evolutionary models in which the AGC kinases emerged from a common ancestral kinase that gave rise not only to different PKC isoforms but also to other kinases such as PKA and PKG, underlining the importance of conserved regulatory mechanisms across species (hardianto2017structuralbioinformaticsstudies pages 17-21, silnitsky2023anupdateon pages 1-2, alexander2015theconciseguide pages 2-3).  
   The divergence of PKCε from the conventional and atypical isoforms is further supported by differences in domain organization; for instance, while conventional PKCs possess a calcium-binding C2 domain, PKCε and its novel counterparts lack a fully functional C2 domain and are thus calcium-independent. Such diagnostic features not only highlight its phylogenetic placement within the novel PKC subfamily but also underscore the evolutionary pressure to develop alternative modes of regulation that rely prominently on lipid second messengers—specifically diacylglycerol and phosphatidylserine—for enzyme activation (hardianto2017structuralbioinformaticsstudies pages 17-21, alexander2015theconciseguide pages 2-3).  
   Moreover, comparative analyses of kinase catalytic domains place PKCε within an evolutionary lineage that can be traced back to the last eukaryotic common ancestor (LECA), positioning it among a conserved group of AGC kinases that share kinship with other central regulatory enzymes such as protein kinase B (AKT) and p90 ribosomal S6 kinase (RSK). This phylogenetic framework is essential for understanding how subtle variations in regulatory and catalytic regions among kinases like PKCε underlie their distinct substrate specificities and modes of activation in higher eukaryotes (hardianto2017structuralbioinformaticsstudies pages 8-11, alexander2015theconciseguide pages 1-2).
2. Reaction Catalyzed  
   PKCε catalyzes the transfer of a phosphate group from ATP to specific serine or threonine residues on substrate proteins. In this canonical phosphorylation reaction, ATP and a protein substrate – containing an available hydroxyl group on a serine or threonine residue – are converted to ADP and a phosphorylated protein, along with the concomitant release of a proton. The chemical reaction can be summarized as follows:  
   ATP + [protein]-(L-serine or L-threonine) → ADP + [protein]-phosphoserine/threonine + H⁺ (alexander2015theconciseguide pages 3-4, webb2000proteinkinasec pages 2-3).  
   This reaction is common among protein kinases general to the AGC family, illustrating a conserved catalytic mechanism that is driven by the binding of ATP in the active site and the subsequent nucleophilic attack on the substrate’s hydroxyl group (alexander2015theconciseguide pages 3-4).
3. Cofactor Requirements  
   The enzymatic activity of PKCε depends on the presence of key cofactors. Foremost among these is Mg²⁺, which is essential for the coordination of ATP within the catalytic cleft; Mg²⁺ ions facilitate the proper positioning of ATP for effective phosphoryl transfer. Unlike conventional PKCs, PKCε is characteristically calcium-independent due to the absence of a functional C2 binding domain; instead, its activation is reliant on lipid-derived cofactors. Specifically, diacylglycerol (DAG) and phosphatidylserine act as critical activators by binding to the tandem C1 domains within the regulatory region. These lipid cofactors mediate the translocation of PKCε from the cytosol to the cellular membrane, where substrate access is enhanced, and allow for the conformational changes necessary to relieve autoinhibition (alexander2015theconciseguide pages 1-2, massart2019roleofdiacylglycerol pages 3-3).  
   Thus, while Mg²⁺ serves as the obligatory metal ion coordinating ATP during the phosphoryl transfer reaction, the lipid environment—augmented by DAG and phosphatidylserine—provides the activation trigger that is fundamental to the physiological function of PKCε (alexander2015theconciseguide pages 1-2).
4. Substrate Specificity  
   PKCε exhibits substrate specificity primarily through the phosphorylation of serine and threonine residues within diverse target proteins. Although an explicit consensus sequence analogous to the RxRxxp[ST] motif described for other AGC kinases has not been definitively demarcated for PKCε, its substrate recognition is characterized by a preference for phosphorylation sites that are generally situated in regions flanked by basic amino acids. This predisposition is consistent with its classification as a basophilic kinase. Key substrates of PKCε include cytoskeletal and regulatory proteins implicated in the modulation of cell adhesion, motility, and structural dynamics. For example, PKCε phosphorylates myristoylated alanine-rich C-kinase substrate (MARCKS), a process which in turn modulates downstream kinase activation such as that of focal adhesion kinase (FAK/ PTK2), thereby promoting the spreading of cardiomyocytes. Furthermore, in mesenchymal cells, PKCε phosphorylates vimentin (VIM), an intermediate filament protein critical for maintaining cell shape and directional transport of integrin beta-1 (ITGB1). In epithelial contexts, the phosphorylation of keratin-8 (KRT8) by PKCε regulates the targeting of desmoplakin at desmosomes, thereby influencing cell–cell adhesion (hardianto2017structuralbioinformaticsstudies pages 27-32, silnitsky2023anupdateon pages 11-13).  
   The enzyme’s substrate specificity underlies its ability to control key signaling pathways that dictate cytoskeletal dynamics, cell adhesion, and motility. While the detailed substrate consensus motifs remain less clearly defined than those for some other serine/threonine kinases, PKCε’s substrate selectivity is sufficient to mediate a broad spectrum of cellular responses ranging from integrin-mediated adhesion signaling to the modulation of intermediate filament organization—each function playing an integral role in processes such as cancer cell invasion and tissue remodeling (silnitsky2023anupdateon pages 11-13, silnitsky2023anupdateon pages 17-18).
5. Structure  
   The structural organization of PKCε mirrors the common architectural framework observed in the protein kinase C family and the larger AGC kinase superfamily. The protein is composed of an N-terminal regulatory region and a C-terminal catalytic domain, which are connected via a flexible hinge region. Within the regulatory region reside tandem C1 domains that are responsible for binding diacylglycerol (DAG) and phorbol esters; these domains mediate the enzyme’s membrane targeting upon activation. Unlike conventional PKCs, PKCε lacks a classical C2 domain for calcium binding, which accounts for its calcium-independent activation mechanism (hardianto2017structuralbioinformaticsstudies pages 17-21, webb2000proteinkinasec pages 2-3).  
   Embedded within the regulatory region is also a pseudosubstrate sequence that functions to autoinhibit the enzyme under resting conditions by occluding the substrate-binding site in the catalytic domain. Upon DAG binding, a conformational rearrangement leads to the displacement of this pseudosubstrate segment, thus permitting access of substrate proteins to the active site.  
   The catalytic domain of PKCε is further subdivided into two lobes: a smaller, N-terminal lobe predominantly composed of β-sheets, which contains the glycine-rich loop (also known as the P-loop) that is essential for ATP coordination, and a larger, C-terminal lobe made up largely of α-helices. Key structural features within this catalytic domain include the activation loop, which houses the DFG motif critical for magnesium and ATP binding, and an invariant lysine that plays an indispensable role in stabilizing the transition state during phosphoryl transfer (hardianto2017structuralbioinformaticsstudies pages 17-21, alexander2015theconciseguide pages 3-4).  
   Recent molecular dynamics simulations and comparative modeling studies have provided additional insights into the dynamic conformational behavior of PKCε upon activation, revealing that the release of the inhibitory pseudosubstrate and the subsequent rearrangement of the regulatory and catalytic domains are essential for achieving full catalytic competence. The overall three-dimensional structure of PKCε, as predicted by state-of-the-art structural modeling techniques, confirms the canonical kinase fold that is shared broadly across AGC kinases, while also highlighting unique features—such as the configuration of its tandem C1 domains—that underpin its distinct regulatory properties (hardianto2017structuralbioinformaticsstudies pages 8-11, silnitsky2023anupdateon pages 28-29, alexander2015theconciseguide pages 3-4).
6. Regulation  
   Regulation of PKCε is achieved through a combination of post-translational modifications, cofactor binding, and protein–protein interactions that together ensure precise control over its enzymatic activity in response to cellular cues. A critical component of PKCε regulation is its phosphorylation at multiple conserved sites. During the priming process, PKCε undergoes sequential phosphorylation on the activation loop, turn motif, and hydrophobic motif. These phosphorylation events, which are mediated by kinases such as phosphoinositide-dependent kinase-1 (PDK1) and mTORC2, are essential for stabilizing the enzyme in a catalytically competent conformation and protecting it from degradation (hardianto2017structuralbioinformaticsstudies pages 24-27, silnitsky2023anupdateon pages 10-11).  
   Activation of PKCε is further controlled through its interaction with lipid cofactors. The binding of diacylglycerol to the tandem C1 domains results in the translocation of PKCε from the cytosol to the plasma membrane. This translocation not only facilitates an environment enriched with potential substrates but also promotes a conformational change that dislodges the autoinhibitory pseudosubstrate sequence from the catalytic site, thereby unmasking the active site for substrate phosphorylation (hardianto2017structuralbioinformaticsstudies pages 27-32, silnitsky2023anupdateon pages 7-9).  
   In addition, scaffold proteins—most notably receptors for activated C-kinase (RACKs)—specifically bind to the active form of PKCε, directing its localization to defined subcellular microdomains. Such anchoring processes help to narrow the spectrum of substrates accessible to PKCε and fine-tune its signaling output. Other regulatory inputs include oxidative modifications and proteolytic cleavage events that can either enhance or diminish PKCε activity; although these modes of regulation are less thoroughly characterized, they underscore the complexity of PKCε control in vivo (silnitsky2023anupdateon pages 28-29, brognard2008phlippingtheswitch pages 7-8).  
   Thus, post-translational modifications via phosphorylation and the binding of lipid cofactors, coupled with protein–protein interactions with anchoring molecules, form an integrated regulatory network that governs the spatial, temporal, and functional dynamics of PKCε in response to intracellular signals (silnitsky2023anupdateon pages 15-17, hardianto2017structuralbioinformaticsstudies pages 24-27).
7. Function  
   PKCε plays a multifaceted role in cellular signaling by modulating diverse biological processes through the phosphorylation of serine/threonine residues on key substrate proteins. One of its central functions involves the regulation of cytoskeletal dynamics, which is critical for cell adhesion, motility, and migration. In cardiac fibroblasts, for example, PKCε mediates integrin-dependent signaling by activating integrin beta-1 (ITGB1) in response to angiotensin-2; this activation is pivotal for modulating cell adhesion to the extracellular matrix (protein information).  
   In addition, PKCε phosphorylates MARCKS (myristoylated alanine-rich C-kinase substrate), a modification that leads to the activation of focal adhesion kinase (PTK2/FAK). This cascade promotes the spreading of cardiomyocytes, an essential process in the organization and remodeling of cardiac tissue. In mesenchymal cells, PKCε plays a role in the directional transport of ITGB1 by phosphorylating vimentin (VIM), an intermediate filament protein that contributes to the maintenance of cellular architecture and directional migration. Similarly, in epithelial cells, PKCε associates with and phosphorylates keratin-8 (KRT8), a modification that influences the targeting of desmoplakin at desmosomes and, consequently, regulates intercellular adhesion (protein information, hardianto2017structuralbioinformaticsstudies pages 17-21, silnitsky2023anupdateon pages 17-18).  
   Apart from its prominent role in cytoskeletal regulation, PKCε is involved in neuronal growth and ion channel regulation, thereby influencing neurotransmission and neuronal development. In the immune system, PKCε modulates responses that affect inflammation and cell survival, and its aberrant activity has been linked to enhanced cancer cell invasion and resistance to apoptosis. The kinase’s influence on these processes underscores its role as an oncogenic mediator in various cancers, where it contributes to tumor progression by promoting cell proliferation, migration, and survival (silnitsky2023anupdateon pages 17-18, silnitsky2023anupdateon pages 22-23).  
   Furthermore, PKCε’s function extends to the regulation of cell cycle progression and apoptosis, integrating signals from multiple pathways to maintain cellular homeostasis. Its phosphorylation of substrates involved in these processes translates extracellular signals into coordinated intracellular responses that are essential for normal cell function as well as for the development of disease states such as cardiac hypertrophy and metastatic cancers (silnitsky2023anupdateon pages 14-15, silnitsky2023anupdateon pages 18-19).  
   Overall, the versatility of PKCε in modulating diverse signaling cascades places it at a central node in the regulation of cell adhesion, cytoskeletal organization, cell cycle progression, and cell survival—all of which are critical for both normal physiological processes and pathologic conditions (hardianto2017structuralbioinformaticsstudies pages 27-32, silnitsky2023anupdateon pages 17-18).
8. Other Comments  
   Numerous efforts have been devoted to the development of selective inhibitors targeting PKCε due to its involvement in diseases such as cancer, cardiovascular disorders, and inflammatory conditions. Structure–activity relationship studies, for instance, have focused on balanol analogues—specifically fluorinated variants—that exhibit enhanced selectivity for PKCε over closely related kinases such as protein kinase A (PKA). Stereospecific fluorination at the C5(S) position of balanol analogues has been shown to cooperatively enhance binding affinity to a conserved invariant lysine within the ATP-binding pocket of PKCε, thereby providing a structural basis for isoform-selective inhibition (hardianto2017structuralbioinformaticsstudies pages 163-167, silnitsky2023anupdateon pages 21-22).  
   Additional classes of inhibitors, including bisindolylmaleimide derivatives and DAG-lactone analogues, have been explored for their ability to modulate PKCε activity; however, the high conservation of the catalytic domain among PKC isoforms poses a significant challenge for achieving absolute specificity. As a result, many inhibitors currently available inhibit multiple PKC isozymes, which can complicate their clinical application (silnitsky2023anupdateon pages 22-23, webb2000proteinkinasec pages 3-4).  
   PKCε is strongly implicated in the pathogenesis of various human diseases. In cancer, its overexpression and hyperactivation have been correlated with increased tumor cell migration, invasion, and resistance to apoptosis, positioning it as a promising therapeutic target for anticancer strategies. In cardiovascular disease, PKCε has a dual role; although some studies indicate that its activation can confer cardioprotective effects in ischemic preconditioning, aberrant PKCε signaling is also linked to pathological remodeling and hypertrophy, suggesting a context-dependent function (silnitsky2023anupdateon pages 14-15, silnitsky2023anupdateon pages 17-18).  
   Furthermore, PKCε’s involvement in the regulation of immune responses and pain modulation expands its relevance to inflammatory disorders and neurological conditions. Although detailed mutation profiles specific to PRKCE are not thoroughly characterized in the literature provided, alterations in the expression levels and post-translational modifications of PKCε are recognized as contributing factors to its dysregulated signaling in disease states (brognard2008phlippingtheswitch pages 7-8, massart2019roleofdiacylglycerol pages 3-3).  
   Collectively, these findings underscore the potential of PKCε as a therapeutic target and highlight the ongoing efforts to refine inhibitor design to achieve greater isoform specificity. Further research into the structural and regulatory nuances of PKCε is likely to foster the development of novel pharmacological agents able to modulate its activity in a disease-specific manner (silnitsky2023anupdateon pages 37-38, webb2000proteinkinasec pages 1-2, alexander2015theconciseguide pages 4-6).

References

1. (hardianto2017structuralbioinformaticsstudies pages 17-21): A Hardianto. Structural bioinformatics studies of fluorinated balanol analogues as protein kinase c inhibitors. Unknown journal, 2017.
2. (hardianto2017structuralbioinformaticsstudies pages 24-27): A Hardianto. Structural bioinformatics studies of fluorinated balanol analogues as protein kinase c inhibitors. Unknown journal, 2017.
3. (silnitsky2023anupdateon pages 7-9): Shmuel Silnitsky, Samuel J. S. Rubin, Mulate Zerihun, and Nir Qvit. An update on protein kinases as therapeutic targets—part i: protein kinase c activation and its role in cancer and cardiovascular diseases. International Journal of Molecular Sciences, 24:17600, Dec 2023. URL: https://doi.org/10.3390/ijms242417600, doi:10.3390/ijms242417600. This article has 24 citations and is from a peer-reviewed journal.
4. (alexander2015theconciseguide pages 1-2): Stephen PH Alexander, Doriano Fabbro, Eamonn Kelly, Neil Marrion, John A Peters, Helen E Benson, Elena Faccenda, Adam J Pawson, Joanna L Sharman, Christopher Southan, and Jamie A Davies. The concise guide to pharmacology 2015/16: enzymes. British Journal of Pharmacology, 172:6024-6109, Dec 2015. URL: https://doi.org/10.1111/bph.13354, doi:10.1111/bph.13354. This article has 577 citations and is from a highest quality peer-reviewed journal.
5. (alexander2015theconciseguide pages 2-3): Stephen PH Alexander, Doriano Fabbro, Eamonn Kelly, Neil Marrion, John A Peters, Helen E Benson, Elena Faccenda, Adam J Pawson, Joanna L Sharman, Christopher Southan, and Jamie A Davies. The concise guide to pharmacology 2015/16: enzymes. British Journal of Pharmacology, 172:6024-6109, Dec 2015. URL: https://doi.org/10.1111/bph.13354, doi:10.1111/bph.13354. This article has 577 citations and is from a highest quality peer-reviewed journal.
6. (hardianto2017structuralbioinformaticsstudies pages 163-167): A Hardianto. Structural bioinformatics studies of fluorinated balanol analogues as protein kinase c inhibitors. Unknown journal, 2017.
7. (hardianto2017structuralbioinformaticsstudies pages 27-32): A Hardianto. Structural bioinformatics studies of fluorinated balanol analogues as protein kinase c inhibitors. Unknown journal, 2017.
8. (hardianto2017structuralbioinformaticsstudies pages 8-11): A Hardianto. Structural bioinformatics studies of fluorinated balanol analogues as protein kinase c inhibitors. Unknown journal, 2017.
9. (massart2019roleofdiacylglycerol pages 3-3): J. Massart and J. Zierath. Role of diacylglycerol kinases in glucose and energy homeostasis. Trends in Endocrinology & Metabolism, 30:603-617, Jul 2019. URL: https://doi.org/10.1016/j.tem.2019.06.003, doi:10.1016/j.tem.2019.06.003. This article has 36 citations.
10. (silnitsky2023anupdateon pages 1-2): Shmuel Silnitsky, Samuel J. S. Rubin, Mulate Zerihun, and Nir Qvit. An update on protein kinases as therapeutic targets—part i: protein kinase c activation and its role in cancer and cardiovascular diseases. International Journal of Molecular Sciences, 24:17600, Dec 2023. URL: https://doi.org/10.3390/ijms242417600, doi:10.3390/ijms242417600. This article has 24 citations and is from a peer-reviewed journal.
11. (silnitsky2023anupdateon pages 10-11): Shmuel Silnitsky, Samuel J. S. Rubin, Mulate Zerihun, and Nir Qvit. An update on protein kinases as therapeutic targets—part i: protein kinase c activation and its role in cancer and cardiovascular diseases. International Journal of Molecular Sciences, 24:17600, Dec 2023. URL: https://doi.org/10.3390/ijms242417600, doi:10.3390/ijms242417600. This article has 24 citations and is from a peer-reviewed journal.
12. (silnitsky2023anupdateon pages 11-13): Shmuel Silnitsky, Samuel J. S. Rubin, Mulate Zerihun, and Nir Qvit. An update on protein kinases as therapeutic targets—part i: protein kinase c activation and its role in cancer and cardiovascular diseases. International Journal of Molecular Sciences, 24:17600, Dec 2023. URL: https://doi.org/10.3390/ijms242417600, doi:10.3390/ijms242417600. This article has 24 citations and is from a peer-reviewed journal.
13. (silnitsky2023anupdateon pages 14-15): Shmuel Silnitsky, Samuel J. S. Rubin, Mulate Zerihun, and Nir Qvit. An update on protein kinases as therapeutic targets—part i: protein kinase c activation and its role in cancer and cardiovascular diseases. International Journal of Molecular Sciences, 24:17600, Dec 2023. URL: https://doi.org/10.3390/ijms242417600, doi:10.3390/ijms242417600. This article has 24 citations and is from a peer-reviewed journal.
14. (silnitsky2023anupdateon pages 15-17): Shmuel Silnitsky, Samuel J. S. Rubin, Mulate Zerihun, and Nir Qvit. An update on protein kinases as therapeutic targets—part i: protein kinase c activation and its role in cancer and cardiovascular diseases. International Journal of Molecular Sciences, 24:17600, Dec 2023. URL: https://doi.org/10.3390/ijms242417600, doi:10.3390/ijms242417600. This article has 24 citations and is from a peer-reviewed journal.
15. (silnitsky2023anupdateon pages 17-18): Shmuel Silnitsky, Samuel J. S. Rubin, Mulate Zerihun, and Nir Qvit. An update on protein kinases as therapeutic targets—part i: protein kinase c activation and its role in cancer and cardiovascular diseases. International Journal of Molecular Sciences, 24:17600, Dec 2023. URL: https://doi.org/10.3390/ijms242417600, doi:10.3390/ijms242417600. This article has 24 citations and is from a peer-reviewed journal.
16. (silnitsky2023anupdateon pages 18-19): Shmuel Silnitsky, Samuel J. S. Rubin, Mulate Zerihun, and Nir Qvit. An update on protein kinases as therapeutic targets—part i: protein kinase c activation and its role in cancer and cardiovascular diseases. International Journal of Molecular Sciences, 24:17600, Dec 2023. URL: https://doi.org/10.3390/ijms242417600, doi:10.3390/ijms242417600. This article has 24 citations and is from a peer-reviewed journal.
17. (silnitsky2023anupdateon pages 21-22): Shmuel Silnitsky, Samuel J. S. Rubin, Mulate Zerihun, and Nir Qvit. An update on protein kinases as therapeutic targets—part i: protein kinase c activation and its role in cancer and cardiovascular diseases. International Journal of Molecular Sciences, 24:17600, Dec 2023. URL: https://doi.org/10.3390/ijms242417600, doi:10.3390/ijms242417600. This article has 24 citations and is from a peer-reviewed journal.
18. (silnitsky2023anupdateon pages 22-23): Shmuel Silnitsky, Samuel J. S. Rubin, Mulate Zerihun, and Nir Qvit. An update on protein kinases as therapeutic targets—part i: protein kinase c activation and its role in cancer and cardiovascular diseases. International Journal of Molecular Sciences, 24:17600, Dec 2023. URL: https://doi.org/10.3390/ijms242417600, doi:10.3390/ijms242417600. This article has 24 citations and is from a peer-reviewed journal.
19. (silnitsky2023anupdateon pages 28-29): Shmuel Silnitsky, Samuel J. S. Rubin, Mulate Zerihun, and Nir Qvit. An update on protein kinases as therapeutic targets—part i: protein kinase c activation and its role in cancer and cardiovascular diseases. International Journal of Molecular Sciences, 24:17600, Dec 2023. URL: https://doi.org/10.3390/ijms242417600, doi:10.3390/ijms242417600. This article has 24 citations and is from a peer-reviewed journal.
20. (silnitsky2023anupdateon pages 37-38): Shmuel Silnitsky, Samuel J. S. Rubin, Mulate Zerihun, and Nir Qvit. An update on protein kinases as therapeutic targets—part i: protein kinase c activation and its role in cancer and cardiovascular diseases. International Journal of Molecular Sciences, 24:17600, Dec 2023. URL: https://doi.org/10.3390/ijms242417600, doi:10.3390/ijms242417600. This article has 24 citations and is from a peer-reviewed journal.
21. (webb2000proteinkinasec pages 2-3): Benjamin L J Webb, Stuart J Hirst, and Mark A Giembycz. Protein kinase c isoenzymes: a review of their structure, regulation and role in regulating airways smooth muscle tone and mitogenesis. British Journal of Pharmacology, 130:1433-1452, Aug 2000. URL: https://doi.org/10.1038/sj.bjp.0703452, doi:10.1038/sj.bjp.0703452. This article has 231 citations and is from a highest quality peer-reviewed journal.
22. (alexander2015theconciseguide pages 3-4): Stephen PH Alexander, Doriano Fabbro, Eamonn Kelly, Neil Marrion, John A Peters, Helen E Benson, Elena Faccenda, Adam J Pawson, Joanna L Sharman, Christopher Southan, and Jamie A Davies. The concise guide to pharmacology 2015/16: enzymes. British Journal of Pharmacology, 172:6024-6109, Dec 2015. URL: https://doi.org/10.1111/bph.13354, doi:10.1111/bph.13354. This article has 577 citations and is from a highest quality peer-reviewed journal.
23. (alexander2015theconciseguide pages 4-6): Stephen PH Alexander, Doriano Fabbro, Eamonn Kelly, Neil Marrion, John A Peters, Helen E Benson, Elena Faccenda, Adam J Pawson, Joanna L Sharman, Christopher Southan, and Jamie A Davies. The concise guide to pharmacology 2015/16: enzymes. British Journal of Pharmacology, 172:6024-6109, Dec 2015. URL: https://doi.org/10.1111/bph.13354, doi:10.1111/bph.13354. This article has 577 citations and is from a highest quality peer-reviewed journal.
24. (brognard2008phlippingtheswitch pages 7-8): John Brognard and Alexandra C. Newton. Phlipping the switch on akt and protein kinase c signaling. Trends in Endocrinology & Metabolism, 19:223-230, Aug 2008. URL: https://doi.org/10.1016/j.tem.2008.04.001, doi:10.1016/j.tem.2008.04.001. This article has 233 citations.
25. (webb2000proteinkinasec pages 1-2): Benjamin L J Webb, Stuart J Hirst, and Mark A Giembycz. Protein kinase c isoenzymes: a review of their structure, regulation and role in regulating airways smooth muscle tone and mitogenesis. British Journal of Pharmacology, 130:1433-1452, Aug 2000. URL: https://doi.org/10.1038/sj.bjp.0703452, doi:10.1038/sj.bjp.0703452. This article has 231 citations and is from a highest quality peer-reviewed journal.
26. (webb2000proteinkinasec pages 3-4): Benjamin L J Webb, Stuart J Hirst, and Mark A Giembycz. Protein kinase c isoenzymes: a review of their structure, regulation and role in regulating airways smooth muscle tone and mitogenesis. British Journal of Pharmacology, 130:1433-1452, Aug 2000. URL: https://doi.org/10.1038/sj.bjp.0703452, doi:10.1038/sj.bjp.0703452. This article has 231 citations and is from a highest quality peer-reviewed journal.